Cannabinoids inhibit tumor angiogenesis in animal models of cancer, but the mechanism of their antiangiogenic action is still unknown. By using cDNA arrays and other procedures, Blázquez et al. show that cannabinoids depress the major tumor-angiogenesis pathway, namely the vascular endothelial growth factor (VEGF) pathway, by decreasing VEGF production and VEGF receptor-2 activation in cultured glioma cells, mouse gliomas, and two patients with glioblastoma multiforme. These observations indicate that blockade of the VEGF pathway may constitute a novel pharmacological target for cannabinoid-based antitumoral therapies. The cover image shows C6 glioma cells cultured with JWH-133 and fumonisin B1.VEGFR-2 activation (anti-VEGFR-2 PY1214 antibody, green) and expression (antitotal VEGFR-2 antibody, red) were determined by confocal microscopy. Cell nuclei are stained in blue. For details, see the article by Blázquez et al. on page 5617 of this issue.

[Table of Contents]